Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer's Disease
核心洞察
Arctic Therapeutics (搜索) has received European Medicines Agency (搜索) authorization to initiate a Phase IIa clinical trial evaluating AT-001 in patients with mild cognitive impairment (搜索) or mild Alzheimer's disease (搜索).
The EMA has granted Orphan Drug Designation to AT-001 for hereditary cystatin C amyloid angiopathy (搜索), a rare familial dementia (搜索) condition.
The 12-month multicentre trial will assess AT-001's safety and biomarker-based efficacy using advanced blood-based biomarkers and brain imaging techniques.
Arctic Therapeutics (搜索) (ATx), an Iceland-based clinical-stage biopharmaceutical company, has received European Medicines Agency (搜索) (EMA) authorization to initiate a Phase IIa clinical trial evaluating AT-001 in patients diagnosed with Alzheimer's disease (搜索). The regulatory approval represents a significant expansion of the company's dementia (搜索) treatment program from rare to common forms of the disease.
The multicentre, randomized, double-blind, placebo-controlled, dose-escalation study will assess the safety profile of AT-001, as well as its impact on novel blood-based biomarkers and brain amyloid (搜索) deposition in individuals with mild cognitive impairment (搜索) (MCI) or mild dementia (搜索) due to Alzheimer's disease (搜索).
Regulatory Milestones and Orphan Drug Designation
In addition to the Alzheimer's disease (搜索) study authorization, the EMA has granted AT-001 Orphan Drug Designation (ODD) for the treatment of hereditary cystatin C amyloid angiopathy (搜索) (HCCAA), a rare familial dementia (搜索). HCCAA is an ultra-rare condition marked by amyloid (搜索) buildup in the brain's blood vessels that can cause cerebral haemorrhage, stroke and progressive neurological decline, including dementia.
"The ODD status confirms the ground-breaking nature of AT-001 as a potentially disease-modifying treatment for HCCAA and underpins our expansion into other forms of dementia (搜索), including Alzheimer's," said CEO and co-founder Ivar Hakonarson. "This is a significant milestone and underscores the urgent unmet medical need in HCCAA and provides ATx with an important regulatory milestone to advance AT-001 in this rare and devastating condition."
The current study authorization follows the EMA's authorization last year for ATx to initiate a Phase IIb/III study of AT-001 in HCCAA, a form of hereditary cerebral amyloid angiopathy (搜索) (CAA).
Phase IIa Study Design and Protocol
The study will evaluate the safety, tolerability, and biomarker-based efficacy of AT-001, a small molecule oral therapy, in patients aged 50-85 with mild cognitive impairment (搜索) or mild Alzheimer's disease (搜索). The multicentre trial will be conducted at four sites across Denmark and Iceland in collaboration with Sanos Group (搜索), a global multi-niche CRO.
The trial will enrol patients for 12 months of treatment with escalating oral doses of AT-001. Safety laboratories will be monitored monthly, together with biomarker assessments every three months, MRI at baseline, mid- and end of study, and PET scans at baseline and study completion.
Advanced Biomarker and Imaging Approaches
The study's primary focus is on safety and biomarker efficacy, utilizing cutting-edge diagnostic technologies. Selected biomarkers include plasma pTau217 and total Tau (搜索), measured with Quanterix Simoa® technology to track early tau pathology and neuronal damage. The trial will also monitor Neurofilament Light Chain (NfL) as a marker of axonal injury and neurodegeneration, and toxic amyloid-β oligomers (搜索) measured with the novel SOBA assay to detect synaptotoxic species driving memory loss.
Imaging components include MRI to evaluate brain atrophy and white matter integrity, and PET scans to visualize amyloid (搜索) plaque burden and assess potential reductions with AT-001. Upon completion of the trial, the biomarker and brain amyloid results will be analysed in the context of clinical improvement observed with recent monoclonal antibody-based amyloid reduction therapies.
Company Vision and Scientific Approach
"Alzheimer's disease (搜索) is one of the world's most urgent healthcare challenges. Advances in early diagnosis, combined with treatments that enable earlier intervention, hold the potential to transform how we approach Alzheimer's, as well as other forms of dementia (搜索)," said ATx founder Dr. Hakon Hakonarson. "Through our clinical trials targeting both rare and common forms of dementia, we are pushing the science forward with the goal of not only delaying progression, but ultimately preventing these diseases altogether."
Arctic Therapeutics (搜索) was established in 2015 as a spin-off from the US-based Center for Applied Genomics (搜索) (CAG), a research centre at the Children's Hospital of Philadelphia. The company leverages applied genomics to develop safer, more effective treatments for challenging diseases, with operations in Iceland, the US and multiple collaborations across Europe.